Remedee Labs, a French start-up that specializes in non-pharmaceutical chronic pain management and just announced the positive results of its clinical study on osteoarthritis is strengthening its Board of Directors and its Advisory Board with the addition of two experienced healthcare executives : Florence DUPRÉ and JULIE FOSTER.
Florence Dupré joins the Board of Directors
As a healthcare executive with over 28 years of experience in the field, Florence has contributed to numerous product launches for international pharmaceutical companies. After graduating from ESSEC and École Normale Supérieure ULM, Florence plunged into entrepreneurship, founding the French subsidiaries of BioAlliance Pharma (now Onxeo) and Vifor Pharma. She then joined AbbVie, where she had international responsibility for sales and transformation. Florence then became the President of the French subsidiary of Medtronic, the global healthcare technology leader. Florence has also served as a member of the Board of Directors and the Executive Board of the French National Association for Medical Technology and Industries (SNITEM) and the Management Board of the Rennes University Foundation.
Julie FOSTER joins the Advisory Board
Julie FOSTER is currently the Chief Operating Officer at Cerebral Therapeutics, a U.S. based clinical stage biopharmaceutical company dedicated to developing innovative and de-risked therapies for refractory neurological diseases. She previously spent over 34 years in a range of global executive roles at Medtronic, the medical technology leader worldwide, including as Vice President of Customer Experience at the Diabetes division, Vice President of the Cardiac and Vascular businesses in EMEA, and General Manager of Pain Therapies, where the activities she headed included neuromodulation.
Julie brings international experience and a strategic vision of healthcare, particularly pain care, to Remedee Labs. She will advise Remedee Labs on its development and growth, particularly in the US, where it earned FDA “breakthrough device” designation for its fibromyalgia management solution.
About Remedee Labs
Remedee Labs is a healthtech startup dedicated to chronic pain management. Founded in 2016 by three experts in medical micro and nanotechnology and biomedical research, Remedee Labs has developed an innovative comprehensive solution to change the lives of patients affected by chronic pain. Its solution combines its unique, non-invasive millimeter wave neuromodulation technology (endorphin stimulator wristband) with a digital services platform and personalized multidisciplinary support.
In October 2022, Remedee Labs announced that it was raising €12.2 million from Generali France and other investors to accelerate the market launch of its solution in France and internationally while continuing to develop its neuromodulation technology and expand its service offer.
In 2022, its fibromyalgia management solution also garnered recognition in North America, where it was granted “innovative device” status by the US Food and Drug Administration (FDA) and nominated for the prestigious Galien USA award.
Learn more about the Remedee solution: https://remedee.com
